Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Self-Selection Guidance Needs To Fill In The Gaps – CHPA

This article was originally published in The Tan Sheet

Executive Summary

FDA’s draft guidance on self-selection studies for Rx-to-OTC switches leaves room for details, particularly on appropriate questions, CHPA says. The guidance is an opportunity for FDA to show how it looks at questions, says Barbara Kochanowski, regulatory and scientific affairs VP.


Related Content

Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert
FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts